• Contact us
  • E-Submission

Ewha Med J : The Ewha Medical Journal

OPEN ACCESS
mobile search button mobile menu button
Search
Advanced Search
ABOUT
BROWSE ARTICLES
JOURNAL POLICIES
FOR CONTRIBUTORS

Articles

Page Path

Original Article

Clinical Relevance of EGFR Mutations in Colorectal Cancer Patients

Bo-Young Oh, Ryung-Ah Lee, Soon-Sup Chung, Kwang Ho Kim
The Ewha Medical Journal 2013;36(1):51-57. Published online: March 25, 2013

Department of Surgery, Ewha Womans University School of Medicine, Seoul, Korea.

Corresponding author: Kwang Ho Kim, Department of Surgery, Ewha Womans University School of Medicine, 911-1 Mok-dong, Yangcheon-gu, Seoul 158-710, Korea. Tel: 82-2-2650-5585, Fax: 82-2-2644-7984, eastgate@ewha.ac.kr

Copyright © 2013. Ewha Womans University School of Medicine

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 39 Views
  • 0 Download
prev next

Full Article

Download PDF Download PDF
  • Objectives
    The EGFR plays an important role in tumorigenesis and tumor progression of colorectal cancer, and leads to the activation of intracellular signaling pathways. The use of anti-EGFR-targeted therapy has increased for patients with colorectal cancer, but patients with EGFR mutations will be resistant to anti-EGFR-targeted therapy. The identification of gene mutations is critical in cancer treatment; therefore, the aim of this study is to investigate the incidences of EGFR mutations in colorectal cancer patients in Korea.
  • Methods
    We reviewed 58 colorectal cancer patients who underwent operations between 2003 and 2006, retrospectively. We analyzed their EGFR mutations in 4 loci by DNA sequencing. In addition, we analyzed the correlation between the presence of EGFR mutation and patients' clinicopathologic features.
  • Results
    Of the 58 patients, 35 patients were male and 23 were female. Their mean age was 63.28±11.18 years. Two patients (3.45%) were diagnosed as stage Tis, 7 patients (12.07%) had stage I, 24 patients (41.38%) had stage II, 20 patients (34.48%) had stage III, and 5 patients (8.62%) had stage IV. As a result of mutational analysis, EGFR mutations on exon 20 were detected in 13 patients (22.41%, G→A transitions). EGFR mutations on exon 18, 19 and 21 were not detected. EGFR mutation increased in the earlier stage and the absence of lymph node metastasis (P=0.028).
  • Conclusion
    The incidence of EGFR mutation in Korean colorectal cancer patients is 22.41%. In addition, EGFR mutation significantly increased in the earlier stage and the absence of lymph node metastasis.
  • Keywords: Colorectal cancer; EGFR; Mutation

This article is the Korean version of "Epidermal growth factor receptor mutations in colorectal cancer patients.". Secondary publication (J Korean Soc Coloproctol 2011,27:127-32 doi: 10.3393/jksc.2011.27.3.127).

  • 1. de Castro-Carpeño J, Belda-Iniesta C, Casado Sáenz E, Hernández Agudo E, Feliu Batle J, González Barón M. EGFR and colon cancer: a clinical view. Clin Transl Oncol 2008;10:6-13.
  • 2. Ponz-Sarvisé M, Rodríguez J, Viudez A, Chopitea A, Calvo A, García-Foncillas J, et al. Epidermal growth factor receptor inhibitors in colorectal cancer treatment: What's new? World J Gastroenterol 2007;13:5877-5887.
  • 3. Sameer AS, Chowdhri NA, Abdullah S, Shah ZA, Siddiqi MA. Mutation pattern of K-ras gene in colorectal cancer patients of Kashmir: a report. Indian J Cancer 2009;46:219-225.
  • 4. Yun SH. Molecular targeted therapy in colorectal cancer. J Korean Soc Coloproctol 2004;20:180-188.
  • 5. Kim HA, Lee RA, Hwang DY, Park SH. The significances of EGFR overexpression in colorectal cancer. J Korean Soc Coloproctol 2005;21:36-41.
  • 6. Jang TW, Oak CH, Chang HK, Suo SJ, Jung MH. EGFR and KRAS mutations in patients with adenocarcinoma of the lung. Korean J Intern Med 2009;24:48-54.
  • 7. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-354.
  • 8. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 1990;265:7709-7712.
  • 9. Zhou Y, Li S, Hu YP, Wang J, Hauser J, Conway AN, et al. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res 2006;66:404-411.
  • 10. Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 2001;13:506-513.
  • 11. McKay JA, Murray LJ, Curran S, Ross VG, Clark C, et al. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 2002;38:2258-2264.
  • 12. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007;96:1166-1169.
  • 13. Nagahara H, Mimori K, Ohta M, Utsunomiya T, Inoue H, Barnard GF, et al. Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin Cancer Res 2005;11:1368-1371.
  • 14. Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V, et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer 2008;99:923-929.
  • 15. Park SH, Ha SY, Lee JI, Lee H, Sim H, Kim YS, et al. Epidermal growth factor receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung. J Korean Med Sci 2009;24:448-452.
  • 16. Barber TD, Vogelstein B, Kinzler KW, Velculescu VE. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004;351:2883.
  • 17. Ogino S, Meyerhardt JA, Cantor M, Brahmandam M, Clark JW, Namgyal C, et al. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res 2005;11:6650-6656.
Fig. 1
Sequencing results for EGFR mutation. Partial nucleotide sequences of the wild and mutant in exon 20 of the EGFR gene. (A) Forward; transition of G to A (arrow) leading to substitute methionine for isoleucine (B) Reverse; transition of C to T (arrow).
emj-36-51-g001.jpg
Fig. 2
Overall survival and disease-free survival according to EGFR status. (A) There was no significant difference between EGFR-wild group and EGFR-mutated group on overall survival (P=0.8118). (B) EGFR mutational status was not associated with any significant influence on disease-free survival (P=0.8388).
emj-36-51-g002.jpg
Table 1
Primers used for amplification and sequencing of EGFR genes

*F, forward; †R, reverse.

emj-36-51-i001.jpg
Table 2
Patient's clinicopathologic features

*LN, lymph node; †Tis, tumor in situ.

emj-36-51-i002.jpg
Table 3
Relationship between EGFR mutation and the clinicopathologic features

*EGFR, epithelial growth factor receptor; †Tis, tumor in situ; ‡LN, lymph node.

emj-36-51-i003.jpg

Figure & Data

References

    Citations

    Citations to this article as recorded by  

      Download Citation

      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

      Format:

      Include:

      Clinical Relevance of EGFR Mutations in Colorectal Cancer Patients
      Ewha Med J. 2013;36(1):51-57.   Published online March 25, 2013
      DOI: https://doi.org/10.12771/emj.2013.36.1.51
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Clinical Relevance of EGFR Mutations in Colorectal Cancer Patients
      Ewha Med J. 2013;36(1):51-57.   Published online March 25, 2013
      DOI: https://doi.org/10.12771/emj.2013.36.1.51
      Close

      Figure

      • 0
      • 1
      Clinical Relevance of EGFR Mutations in Colorectal Cancer Patients
      Image Image
      Fig. 1 Sequencing results for EGFR mutation. Partial nucleotide sequences of the wild and mutant in exon 20 of the EGFR gene. (A) Forward; transition of G to A (arrow) leading to substitute methionine for isoleucine (B) Reverse; transition of C to T (arrow).
      Fig. 2 Overall survival and disease-free survival according to EGFR status. (A) There was no significant difference between EGFR-wild group and EGFR-mutated group on overall survival (P=0.8118). (B) EGFR mutational status was not associated with any significant influence on disease-free survival (P=0.8388).

      Fig. 1

      Fig. 2

      Clinical Relevance of EGFR Mutations in Colorectal Cancer Patients

      Primers used for amplification and sequencing of EGFR genes

      *F, forward; †R, reverse.

      Patient's clinicopathologic features

      *LN, lymph node; †Tis, tumor in situ.

      Relationship between EGFR mutation and the clinicopathologic features

      *EGFR, epithelial growth factor receptor; †Tis, tumor in situ; ‡LN, lymph node.
      Table 1 Primers used for amplification and sequencing of EGFR genes

      *F, forward; †R, reverse.

      Table 2 Patient's clinicopathologic features

      *LN, lymph node; †Tis, tumor in situ.

      Table 3 Relationship between EGFR mutation and the clinicopathologic features

      *EGFR, epithelial growth factor receptor; †Tis, tumor in situ; ‡LN, lymph node.

      Table 1

      Table 2

      Table 3

      Ewha Med J : The Ewha Medical Journal

      ABOUT

      BROWSE ARTICLES 

      JOURNAL POLICIES

      FOR CONTRIBUTORS 

      © Ewha Womans University College of Medicine.
      TOP